CN101310770A - 抗癌抗体 - Google Patents

抗癌抗体 Download PDF

Info

Publication number
CN101310770A
CN101310770A CNA2008101103851A CN200810110385A CN101310770A CN 101310770 A CN101310770 A CN 101310770A CN A2008101103851 A CNA2008101103851 A CN A2008101103851A CN 200810110385 A CN200810110385 A CN 200810110385A CN 101310770 A CN101310770 A CN 101310770A
Authority
CN
China
Prior art keywords
cancer
antibody
fragment
cripto
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008101103851A
Other languages
English (en)
Chinese (zh)
Inventor
伊恩·法奎尔·坎贝尔·麦肯奇
邢培祥
胡秀凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Austin Research Institute
Original Assignee
Austin Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austin Research Institute filed Critical Austin Research Institute
Publication of CN101310770A publication Critical patent/CN101310770A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2008101103851A 2001-03-26 2002-03-26 抗癌抗体 Pending CN101310770A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR3958A AUPR395801A0 (en) 2001-03-26 2001-03-26 Antibodies against cancer
AUPR3958 2001-03-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB028073177A Division CN100457781C (zh) 2001-03-26 2002-03-26 抗癌抗体

Publications (1)

Publication Number Publication Date
CN101310770A true CN101310770A (zh) 2008-11-26

Family

ID=3827964

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2008101103851A Pending CN101310770A (zh) 2001-03-26 2002-03-26 抗癌抗体
CNB028073177A Expired - Fee Related CN100457781C (zh) 2001-03-26 2002-03-26 抗癌抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB028073177A Expired - Fee Related CN100457781C (zh) 2001-03-26 2002-03-26 抗癌抗体

Country Status (9)

Country Link
US (1) US7318924B2 (https=)
EP (1) EP1383801A4 (https=)
JP (2) JP4854912B2 (https=)
KR (1) KR100909290B1 (https=)
CN (2) CN101310770A (https=)
AU (3) AUPR395801A0 (https=)
CA (1) CA2442318A1 (https=)
NZ (1) NZ528624A (https=)
WO (1) WO2002077033A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
PL207087B1 (pl) 2001-04-26 2010-10-29 Biogen Przeciwciało, które wiąże się swoiście z białkiem Cripto, zawierająca je kompozycja farmaceutyczna i zastosowanie przeciwciała
AU2003301619A1 (en) * 2002-10-23 2004-05-13 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
CN100567502C (zh) * 2003-04-03 2009-12-09 株式会社康福来 药学制剂
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
DK1670511T3 (da) 2003-09-15 2009-11-23 Res Dev Foundation Cripto-antagonisme af activin- og TGF-B-signalering
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
EP1838736B1 (en) * 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
WO2007061657A2 (en) * 2005-11-14 2007-05-31 The Brigham & Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
WO2008150530A2 (en) * 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
EP3156069B8 (en) 2008-06-20 2020-10-21 Duke University Compositions, methods, and kits for eliciting an immune response
KR100973029B1 (ko) * 2008-10-07 2010-08-11 박지운 알루미늄 합금 가로등 등주
EP2350131B1 (en) * 2008-11-07 2017-06-07 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
WO2012105219A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 抗体療法の効果増強剤
BR112013027119A8 (pt) 2011-04-21 2018-03-06 Seattle Genetics Inc novos conjugados ligante-droga (adcs) e uso dos mesmos
RU2698697C2 (ru) 2013-12-23 2019-08-29 Байер Фарма Акциенгезельшафт Конъюгаты связующего (ADC) с ингибиторами KSP
CA2983311A1 (en) * 2015-04-20 2016-10-27 Minomic International Ltd. Therapeutic antibodies and uses thereof
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
EP3313523A2 (en) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Targeted conjugates of ksp inhibitors
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CN110312534B (zh) 2016-12-21 2023-04-04 拜耳制药股份公司 具有酶促可裂解基团的抗体-药物-缀合物(adc)
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
JP6761889B1 (ja) 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
WO1997044461A2 (en) 1996-05-22 1997-11-27 Novopharm Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
WO2000042832A2 (en) 1999-03-11 2000-07-27 Ardenia Investments Ltd. New compounds for the treatment of cancer
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
NZ525380A (en) 2000-09-18 2008-06-30 Biogen Idec Inc Non-fucosylated forms of Cripto and their use as tumor blocking agents
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
PL207087B1 (pl) 2001-04-26 2010-10-29 Biogen Przeciwciało, które wiąże się swoiście z białkiem Cripto, zawierająca je kompozycja farmaceutyczna i zastosowanie przeciwciała

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用

Also Published As

Publication number Publication date
US7318924B2 (en) 2008-01-15
JP4854912B2 (ja) 2012-01-18
JP2009024014A (ja) 2009-02-05
EP1383801A1 (en) 2004-01-28
CA2442318A1 (en) 2002-10-03
EP1383801A4 (en) 2005-06-01
JP2004534741A (ja) 2004-11-18
NZ528624A (en) 2006-03-31
US20040176576A1 (en) 2004-09-09
KR100909290B1 (ko) 2009-07-24
AU2002240719B2 (en) 2007-01-11
CN100457781C (zh) 2009-02-04
WO2002077033A1 (en) 2002-10-03
AU2007201587A1 (en) 2007-05-03
CN1639194A (zh) 2005-07-13
KR20040010613A (ko) 2004-01-31
AUPR395801A0 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
CN101310770A (zh) 抗癌抗体
CN109369808B (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
KR101683884B1 (ko) 항-ＥｐＣＡＭ 항체 및 이의 용도
CN100410275C (zh) 新的抗igf-ir抗体及其应用
AU2002240719A1 (en) Antibodies against cancer
CN101516912A (zh) 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
CN110914297A (zh) 抗人白细胞介素2抗体及其用途
CN101679485B (zh) 骨桥蛋白的功能表位、针对该单位的单克隆抗体及它们的应用
US20110150906A1 (en) Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer
KR20220012856A (ko) 항 ｐｄ―ｌ１ 항체 및 그의 용도
CN113512117B (zh) 一种可结合cd206的抗体及其应用
Carter et al. Development of herceptin
CN101864398B (zh) 一种抗促性腺激素释放激素受体的单克隆抗体与应用
CN109689691A (zh) IFN-γ-诱导性调节T细胞可转化性抗癌(IRTCA)抗体及其应用
JP5514388B2 (ja) 医薬の調製方法、癌治療薬の調製方法、癌治療のための医薬組成物、癌治療のための医薬組成物の調製方法、ｃｄ５５の補体活性阻害作用の中和方法および補体沈着を向上させる方法
CN110382541A (zh) 人源化抗cd40抗体
CN117003864A (zh) 一种抗Ctrb1的抗体及其用途
CN113698493A (zh) 一种针对VEGF和TGF-β的双功能蛋白及其应用
KR20200090236A (ko) 표피성장인자 수용체에 대한 증가된 친화도를 가지는 항체 및 이의 단편
US20100119514A1 (en) Antibodies Against Cancer
CN121419996A (zh) 用于治疗受试者的her2低表达肿瘤的抗her2抗体
CN119431597A (zh) 抗her2纳米抗体多聚体、抗her2纳米抗体融合蛋白及其药物组合物和应用
HK40005045A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
CN105017424A (zh) 一种egfr抗体可变区及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20081126